An Adenovirus Vector for Efficient RNA Interference–Mediated Suppression of Target Genes in Insulinoma Cells and Pancreatic Islets of Langerhans

  1. James R. Bain12,
  2. Jonathan C. Schisler13,
  3. Koji Takeuchi12,
  4. Christopher B. Newgard124 and
  5. Thomas C. Becker124
  1. 1Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, North Carolina
  2. 2Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina
  3. 3University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
  4. 4Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke University Medical Center, Durham, North Carolina
  1. Address correspondence reprint requests to Thomas C. Becker, PhD, Duke Independence Park Facility, Duke University Medical Center, 4321 Medical Park Dr., Suite 200, Durham, NC 27704. E-mail: thomas.becker{at}duke.edu

Abstract

Silencing gene expression by RNA interference (RNAi) can provide insight into gene function but requires efficient delivery of small interfering RNAs (siRNAs) into cells. Introduction of exogenous nucleic acids can be especially difficult in cultured pancreatic islets. This article describes a method for making recombinant adenoviruses that efficiently drive expression of siRNAs in islet β-cells and a β-cell–derived cell line. Transduction with a virus expressing an siRNA specific for GLUT2 reduced GLUT2 mRNA and protein levels by 80% in the INS-1–derived β-cell line, 832/13, and GLUT2 protein levels by >90% in primary rat islets. Another virus expressing an siRNA specific for glucokinase (GK) caused 80% suppression of GK mRNA and 50% suppression of GK protein levels in 832/13 cells. These experiments validate recombinant adenoviral RNAi vectors as a useful tool for suppression of the expression of specific genes in pancreatic islets and β-cell lines. Advantages of this approach include 1) the high efficiency of adenovirus-mediated gene transfer in insulinoma cell lines and rat islets and 2) the rapidity with which RNAi constructs can be prepared and tested relative to stable-transfection strategies.

Footnotes

  • J.R.B. and J.C.S. contributed equally to this work.

    • Accepted June 16, 2004.
    • Received February 11, 2004.
« Previous | Next Article »Table of Contents